C5252 injection for intracranial glioma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial combines a dose escalation phase to find safe dose levels with a dose expansion phase to look for preliminary signs of activity in adults with recurrent malignant glioma (WHO grade 3-4) who have had prior treatments. C5252 is delivered as a single or multiple intratumoral injections, followed by toxicity monitoring and safety follow-up. Participants must have an Ommaya reservoir, measurable lesions per RANO criteria, and adequate performance status. The study aims to characterize safety/tolerability and gather initial efficacy signals in this setting.

Why it matters

Who can join: the full rules

Key Inclusion Criteria:

* Age ≥ 18 years.
* Confirmed recurrent malignant high-grade (WHO grade 3-4) glioma who have received standard therapy and no available treatment.
* Measurable lesions exist in accordance with RANO criteria.
* Sufficient space for ≥1 mL drug infused into tumor cavity post resection.
* Ommaya reservoir has been placed in the operation area, and drug administration conditions are available.
* Karnofsky Performance Status (KPS) ≥ 60%
* Life expectancy \> 12 weeks.
* No severe hematological, cardiovascular, liver or kidney diseases.
* If the patient is a sexually active female of childbearing potential or if the patient is a sexually active male whose partner is a female of childbearing potential, the patient must use appropriate contraceptive measures for the duration of the treatment and for 6 months afterwards. Female patients of childbearing potential must have a negative serum pregnancy test within 7 days of before the C5252 infusion.
* Capable of understanding and complying with protocol requirements.

Key Exclusion Criteria:

* Inability to undergo MRI examination for any reason.
* Active hemorrhage observed before enrollment.
* Imaging test: a. lesion located in non-cerebral regions; b. there are other lesions outside target tumor cavity; c. extra-cranial metastasis.
* Tumor lesion locates in ventricular system or there is a clear perforation between the tumor cavity and the ventricle after tumor resection.
* History of encephalitis, multiple sclerosis or other central nervous system infections
* Treated with steroid hormones and/or more than 5 mg dexamethasone per day or other immunosuppressive drugs for systemic treatment within 4 weeks.
* Persistent or active infection, and cannot be controlled by treatment.
* Subjects with bleeding tendency or need to take anticoagulant drugs, antiplatelet drugs or non-steroidal anti-inflammatory drugs (NSAIDs) and are unable to discontinue.
* Uncontrolled disease, including but not limited to symptomatic congestive heart failure, unstable angina pectoris.
* Other malignant tumor within 5 years.
* Patients who require an attenuated or live vaccine within 28 days prior to the first trial drug administration and during the study treatment period.
* In the period of recurrent herpes simplex virus infection, with corresponding clinical manifestations.
* Systemic use (other than topical) of anti-HSV drugs
* Prior treatment with any oncolytic virus, cell therapy or gene therapy.
* Participants have a history of splenectomy, organ transplantation, bone marrow transplantation or stem cell transplantation
* Prior antitumor treatment with intracranial implants, such as Carmustine.
* Previous history of allergic reactions to similar biological components such as HSV-1, IL-12 or anti-PD-1 antibodies, or with known allergic reactions to any component of the C5252 prescription, including glycerol.
* Developed ≥Grade 3 irAE during previous immunotherapy
* History of frequent drug use (including "recreational use") or drug abuse (including alcohol abuse) within one year prior to signing the informed consent form.
* Other situation that PI consider subjects not appropriate to participate in the study.

Where it's running

• Tianjin Medical University Cancer Institute & Hospital
  Tianjin, Tianjin Municipality, China Recruiting

Study contacts

• Study coordinator: Xinyi Liu
• Email: xinyi.liu@immviragroup.com
• Phone: 86+512+66202028

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• LMP744 (an indenoisoquinolone) for people with recurrent glioblastoma

  This trial will test whether the drug LMP744 can shrink tumors or slow progression in adults whose glioblastoma has returned after prior treatment.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07416188

• Using 18F-TRX to image solid tumors

  This trial tests whether the 18F-TRX PET tracer can detect tumors in adults with advanced solid tumors such as high‑grade glioma, clear cell renal cell carcinoma, or metastatic castration‑resistant prostate cancer.

  Recruiting Phase 1 University of California, San Francisco · San Francisco, California · NCT06942104

• Testing TNG456 and Abemaciclib in Patients with Solid Tumors Lacking MTAP

  This study is testing a new drug called TNG456, alone and with another drug called abemaciclib, to see if it helps people with advanced solid tumors that have lost a specific gene called MTAP.

  Recruiting at 15 sites Phase 1/2 Tango Therapeutics, Inc. · Scottsdale, Arizona and 14 other locations · NCT06810544

• Testing DSP-0390 in patients with IDH-mutant gliomas

  This study is testing a new drug called DSP-0390 in patients with specific types of brain tumors to see if it helps kill more tumor cells during surgery.

  Recruiting Early Phase 1 Washington University School of Medicine · St Louis, Missouri · NCT06636162

• Cognitive rehabilitation program for patients with diffuse glioma

  This study is testing a new online brain training program to see if it can help people with diffuse glioma improve their memory and thinking skills after treatment.

  Recruiting Institut du Cancer de Montpellier - Val d'Aurelle · Montpellier, Hérault and 7 other locations · NCT06468176

• Proton pulsed reduced-dose-rate radiotherapy for recurrent high-grade glioma

  This trial tests whether a special proton radiation method called PRDR helps people whose fast-growing glioma has come back after prior radiation.

  Recruiting Baptist Health South Florida · Boca Raton, Florida and 1 other locations · NCT06397560

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.